Health
INVESTIGATION: Social media, anonymous websites drive Nigeria’s poorly regulated weight-loss injection market
Published
48 minutes agoon
By
Preport
Toke Makinwa, a popular media personality, disclosed in a Snapchat post on 6 May that she used the prescription weight-loss injectable drug Mounjaro before returning to the gym after giving birth in August 2025.
“Consistency really produces results… I’m not one to pretend or lie. I was on Mounjaro till December; my last dose was on the 31st of December, and I hit the gym hard in January,” Ms Makinwa wrote.
Many entertainment blogs and social media users republished the post. This sparked discussions in the comment section about the drug’s cost and usage, to which vendors responded with adverts for the drug and quoted prices.
What appeared to be ordinary social media marketing led PREMIUM TIMES into a week-long open-source investigation that uncovered a growing digital marketplace where vendors sold the Mounjaro injections without requesting prescriptions and downplayed or denied their side effects.
PREMIUM TIMES also uncovered a network of interconnected anonymous websites that used fabricated testimonials to sell another drug that is still undergoing clinical trials.

Understanding the injections
The products identified during this investigation belong to a class of medicines known as GLP-1 receptor agonists. These are medicines prescribed to reduce appetite by signalling the brain to feel full, while also helping the body control blood sugar levels.
They were originally developed to treat type 2 diabetes, while some have since been approved in several countries like the United States (US), Canada and China for chronic weight management in adults with obesity or overweight under medical supervision.
The two most commonly marketed products by vendors during this investigation were Mounjaro (tirzepatide) and Ozempic (semaglutide).
Mounjaro, manufactured by Eli Lilly, a US-based pharmaceutical company, is a prescription-only injectable, approved to improve blood sugar control in people with type 2 diabetes. Mounjaro is also marketed under the brand name Zepbound for chronic weight management in eligible adults.
Ozempic, on the other hand, is manufactured by Novo Nordisk. It is likewise a prescription-only medicine containing semaglutide, a GLP-1 receptor agonist originally developed for adults with type 2 diabetes.
PREMIUM TIMES also found that some vendors were marketing Retatrutide, an experimental medicine developed by Eli Lilly.
Retatrutide is not yet available for public use and remains in Phase three clinical trials, according to Eli Lilly’s Frequently Asked Questions (FAQ). The World Health Organisation (WHO) described the clinical trial phase as the final stage of testing before a new drug is considered for approval. If successful, Eli Lilly says the drug could be used to treat obesity, type 2 diabetes and joint-related conditions.
PREMIUM TIMES found that these injectables marketed by these vendors do not appear on the public product registration database of the National Agency for Food and Drug Administration and Control (NAFDAC). Despite this, the products were sold online with nationwide delivery options without prescriptions or evidence of medical supervision.
From demand to marketplace
PREMIUM TIMES reviewed the comment sections of Instagram posts by Lindaikejiblog and Yabaleftonline that amplified Toke Makinwa’s Snapchat post.
In response to Lindaikejiblog’s Instagram post, several users asked where they could buy Mounjaro.
One user, chekwubejenifer, wrote: “Where will I see Mounjaro buy o?”
Another user, iamugomsinachi, commented: “Once money touch my hand, me self go take my own Mounjaro.”
Vendors responded quickly to these questions by openly advertising in the comment section.

PREMIUM TIMES contacted bodyng_aesthetic_clinic, which claimed to sell Mounjaro “at an unbeatable price” through the WhatsApp link provided on its profile, to understand how the products were being sold.
The account, with over 9,600 Instagram followers at the time of this investigation, described the injections as “very effective” and immediately asked how much weight the prospective buyer wanted to lose.
When asked about possible side effects, the vendor replied that there were none.
Another vendor, identified through a sponsored Instagram advertisement, operated under the name Abuja Massues. The account described itself as a spa and therapy business and had more than 7,000 followers.
At the time PREMIUM TIMES contacted the business, it was advertising what it called a “CEO Birthday Promo,” offering three categories of weight-loss injections: Basic (N100,000), Premium (N180,000) and VIP (N250,000) per shot.
Like the first vendor, it assured the reporter that the injections had “no side effects.”

In a voice note sent to this reporter on Instagram, the third vendor repeatedly dismissed concerns about the medicines’ safety.
“There’s no side effect, not at all, not at all, not at all, none,” the vendor claimed.
However, the vendors’ claim contradicts the manufacturer’s safety information. Eli Lilly warns that Mounjaro may cause common side effects such as nausea, diarrhoea, vomiting, constipation, indigestion, and abdominal pain.
Other adverse risks include pancreatitis, severe allergic reactions, gallbladder problems, and kidney injury resulting from dehydration.
Oladapo Ashiru, an endocrinologist and former president of the Academy of Medicine Specialities of Nigeria (AMSN), also confirmed the claim is false, highlighting the serious risks as listed by the manufacturer.
Mr Ashiru explained that patients should undergo proper clinical assessment before starting treatment and be monitored throughout treatment. According to him, patients should undergo baseline assessments, including a blood sugar test, a full blood count, and other routine tests, before starting GLP-1 treatment.
He also shared how he managed a patient in Nigeria who developed severe hypovolaemia following unsupervised use of the injectables.
Hypovolaemia is a medical condition characterised by a critical decrease in circulating blood or fluid volume in the body.

The third vendor compared GLP-1 medicines to different strengths of paracetamol and vitamin C tablets to explain why Mounjaro “works faster” than Ozempic.
The vendor also acknowledged that the medicines had not been approved by NAFDAC and disclosed that importers typically present a doctor’s prescription to bring them into Nigeria.
“I don’t know why NAFDAC has not approved it, to be sincere,” she said.
Despite this acknowledgement, she continued encouraging the purchase of the injections and discussed dosage schedules and pricing.
To verify the vendors’ claims, PREMIUM TIMES submitted a Freedom of Information (FOI) request to NAFDAC on 22 June, seeking clarification on the registration status of GLP-1 weight-loss injectables.
In a response dated 25 June and signed by the agency’s Director-General, Mojisola Adeyeye, NAFDAC refused to make a categorical statement on the registration status of Mounjaro, Ozempic, and Retatrutide. Instead, the drug regulator provided a general response to our specific question on the registration status of the three injectables. It stated that medicines intended for commercial distribution in Nigeria are generally required to undergo registration before marketing.
The agency noted that certain unregistered medicines may be imported through “controlled access pathways” under defined regulatory conditions. It did not, however, state whether the three drugs were imported through the “controlled access pathways.”
However, before this investigation, NAFDAC issued public alerts in 2023 and 2024, warning that Ozempic was not registered in Nigeria and that falsified versions of the medicine were circulating in the country.
A network of anonymous websites
While trying to better understand how the weight-loss injections marketed by vendors work and who manufactures them, PREMIUM TIMES searched online for more information about the products.
Among Google’s top search results was mounjaronigeria.com. At first glance, the website appeared to be an educational platform, with a disclaimer at the top of the page stating that its content was “for educational purposes only.” The website claims that it does not sell, supply, or distribute Mounjaro.

A closer look, however, revealed something different. The website contained a fully functional order form through which visitors could select a product, provide their delivery address, weight and WhatsApp number, and consent to being contacted by a ‘medical consultant’ about their treatment plan.

No prescription was required before submitting the request, and no information was provided about the identity or qualifications of the purported medical consultants.
While reviewing mounjaronigeria.com, PREMIUM TIMES noticed hyperlinks embedded on the homepage directing visitors to three other websites: slimnaija.com, naijatrim.com and naijapeptides.com. The links led to separate but similar platforms, all promoting the same weight-loss products with nearly identical designs and marketing styles.
Further Google searches also suggested mounjaro.ng, another standalone website targeting Nigerians interested in GLP-1 weight-loss injections.
Mapping the website network
To determine whether the websites were operated independently or by the same entity, PREMIUM TIMES conducted WHOIS domain registration searches, which provide website identification and contact information.
The results revealed striking similarities. slimnaija.com and naijatrim.com were both registered on 17 January 2026. mounjaronigeria.com was registered eight days later, on 25 January.
Naijapeptides.com and mounjaro.ng were created on 6 January and 3 February, respectively.
All five domains were registered through Cloudflare with registrant information hidden behind the company’s privacy protection service.
While privacy protection is not unusual on its own, the matching registration timeline, similar website design and overlapping content suggested the sites were unlikely to be unrelated.
A manual review of each platform reinforced that suspicion. All five promoted GLP-1 medicines using similar language, comparable pricing structures and near-identical sales pitches.

Fake testimonials and experimental medicines
The investigation found misleading claims across the websites. slimnaija.com and naijatrim.com displayed testimonials attributed to customers identified as Chioma F. and Adaeze A., complete with photographs and claims of losing 19kg and 23kg, respectively.

To verify the testimonials, PREMIUM TIMES conducted reverse image searches using Google Lens. The photographs were traced to Unsplash, a free stock photography website.
There was no evidence that the people pictured were Nigerians or had ever used the advertised products. The testimonials appeared to have been fabricated.
The websites also advertised Retatrutide, an experimental medicine still undergoing Phase III clinical trials. The websites described it as a “lyophilised triple-agonist peptide vial for research use only” and listed Retatrutide 10mg for N198,000 and 20mg for N279,000, alongside an “Add to Cart” option.
Meanwhile, naijapeptides.com attempted to establish credibility by citing published medical studies, linking to PubMed articles and claiming its products were “99% lab verified.” It also referenced FDA approval in a way that suggested the products carried official regulatory endorsement.
However, FDA approval applies to specific medicines approved for the United States market and does not authorise compounded peptides or products marketed in Nigeria.

What Nigerian law says
Commenting on PREMIUM TIMES’ findings, Bernard Okpi, a human rights lawyer and health law advocate, said Nigerian law prohibits the online advertisement and sale of prescription medicines to the general public.
Mr Okpi, who is the managing partner at OBA Attorneys, said, “Pursuant to Regulation 4(2) of the NAFDAC Drug and Related Products Advertisement Regulations 2021, prescription medicines cannot be advertised via online media, digital storefronts, social media, or broadcast channels.
“By Regulation 2(3)(a), promotional claims for prescription drugs are strictly restricted to peer-reviewed medical and scientific journals intended exclusively for healthcare professionals.”
He further explained that Section 1(1) of the Food, Drugs and Related Products (Registration, etc.) Act, Cap. F33, Laws of the Federation of Nigeria 2004, prohibits the manufacture, importation, advertisement, sale or distribution of drug products that have not been registered by NAFDAC.
“Selling, stocking or distributing unregistered pharmaceutical products in Nigeria attracts severe criminal, civil and administrative liabilities,” he said.

Mr Okpi said individuals and companies that sell unregistered medicines may face criminal prosecution, fines, imprisonment, forfeiture of products and other regulatory sanctions.
Addressing websites selling Retatrutide with disclaimers such as “Research Use Only” or “For Educational Purposes Only,” he said such labels do not shield operators from liability if the products are being marketed or supplied for human consumption.
“Placing an ‘educational purposes only’ disclaimer on an e-commerce website that sells or facilitates the purchase of unregistered drugs to Nigerian consumers is illegal and does not negate criminal liability,” he said.
According to him, operating a website that processes orders for prescription medicines without the required licence also breaches Nigerian law and may attract regulatory sanctions.
A shared contact
The similarities between the websites prompted another question. Were they being operated by the same people? To answer this, PREMIUM TIMES clicked the WhatsApp links on both slimnaija.com and naijatrim.com, which redirected users to the same telephone number:+1 (469) 602-0875, a United States number with a Texas area code.
When this reporter contacted the number posing as a prospective buyer, the operator immediately sent a product catalogue containing dosage options, prices and nationwide delivery information.
Retatrutide was offered at N200,000 for 10 mg, N300,000 for 20 mg, and N450,000 for 30 mg. The operator did not request a prescription or ask about the buyer’s medical history.
Seeking to identify the business behind the operation, PREMIUM TIMES requested payment details. The operator provided a bank account in the name of Velorix Nigeria Ltd, providing the first identifiable lead in the investigation.
PREMIUM TIMES searched the Corporate Affairs Commission (CAC) database to determine who owned the company and obtained the status report for the full details of Velorix Nigeria Ltd.
According to the report, the company was incorporated on 7 February 2026, about two weeks after the first domains in the website network were registered. The company’s sole registered director and shareholder is Samson Olufuwa.
The timing was notable, as the company was registered shortly after the websites were created and was the payment destination for products marketed across the network.
PREMIUM TIMES also searched NAFDAC’s public product registration database for the medicines being advertised, including Mounjaro, Ozempic and Retatrutide. The search did not identify these products on the agency’s registered product database.
Right of reply
Having linked the websites, payment details and company registration, PREMIUM TIMES contacted Mr Olufuwa via the email and WhatsApp contact provided in the status report by 10 a.m on 22 June.
By 5 p.m the same day, all five websites became inaccessible. The sites had remained online throughout the investigation, but went offline shortly after PREMIUM TIMES sought a response.
Before making contact, PREMIUM TIMES preserved archived copies of the websites using archive.ph.

A response eventually came from Mr Olufuwa on 24 June, through his lawyer, Chinualum Mmuozoba of Acreage Associates.
In a written response, the lawyer said Velorix Nigeria Ltd does not own or operate the websites identified during the investigation.
Instead, he said the company merely provided technology-related services to a third-party client.
The letter also stated that after becoming aware of PREMIUM TIMES‘ findings, Velorix had “immediately suspended the services it was providing, including the technical payment facility.”
More clarifications from NAFDAC
On websites selling Retatrutide to random individuals with the tag “Research Use Only”, NAFDAC stated in its response that products bearing that label are not authorised for routine human use.
It added that any product represented for human consumption falls within Nigeria’s regulatory requirements and may be subject to regulatory action if marketed or supplied outside approved pathways.
PREMIUM TIMES requested records of adverse events linked to unsupervised use of GLP-1 medicines; NAFDAC said it operates a national pharmacovigilance programme that continuously monitors the safety of medicines.
However, it declined to release the requested reports, stating that “specific case data and report details are handled in accordance with applicable confidentiality, patient protection and regulatory disclosure provisions.”
The agency also said it is intensifying the monitoring of online medicine sales and may take enforcement actions, including investigations, seizures, sanctions, prosecution and public alerts, where violations are identified.
NAFDAC added that the unauthorised online sale of medicines requires a coordinated response involving regulators, digital platforms, telecommunications companies, law enforcement agencies, healthcare professionals and consumers.
This report was produced under the 2026 Kwame Karikari Fact-checking and OSINT Fellowship, co-hosted by DUBAWA and the Digital Technology, Artificial Intelligence, and Information Disorder Analysis Centre (DAIDAC), with support from the Centre for Journalism Innovation and Development (CJID).
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.
You may like
-
NAFDAC warns of suspected counterfeit asthma medication found in Nigerian market
-
Nigeria’s GBB to deploy 54 smart police stations after Gombe pilot – Technology Times
-
Govt pegs 1.5% stamp duty on cryptocurrency conversions in Nigeria, new tax rules reshape digital asset market – Technology Times
-
Fidson, Nigeria’s largest pharmaceutical company, delivers N3.6 billion dividend to shareholders
Health
PT Health Watch: What new mothers should know about postpartum care before leaving hospital
Published
13 hours agoon
August 8, 2026By
Preport
Postpartum recovery is often overshadowed by labour and childbirth, yet the period immediately after delivery is critical to the health and survival of both mother and baby.
According to the World Health Organisation (WHO), the first six weeks after childbirth are a critical period for the survival and wellbeing of both mothers and newborns, as well as for supporting the baby’s healthy development and the mother’s physical and mental recovery.
The WHO also recommends that women and newborns receive information, reassurance and support from health workers throughout the postnatal period.
Speaking with PT Health Watch, a retired midwife, Mary Augustine, said the weeks following childbirth are as important as labour and delivery in preventing complications and supporting the physical and mental wellbeing of mothers and their newborns.
She stressed the need for health workers to provide every new mother with practical guidance on caring for herself and her baby before discharge from the hospital.
Essential care before discharge
Mrs Augustine said mothers should be taught how to breastfeed correctly, noting that proper positioning and attachment are important for effective feeding.
She also stressed the importance of proper umbilical cord care, explaining that keeping the cord clean and dry can help prevent infections.
According to her, mothers should also be taught how to bathe their babies safely, recognise when nappies need to be changed and keep the newborn’s airway clear to reduce the risk of breathing difficulties.
She said these basic care practices are essential for protecting newborns from preventable illnesses and discomfort.
Preventable complications
Mrs Augustine noted that many women remain silent about the challenges they face after childbirth because they believe such experiences are normal.
She explained that untreated breast pain, for instance, may discourage mothers from breastfeeding, while other complications can develop within weeks after delivery if they do not receive timely care.
These include postpartum haemorrhage, puerperal sepsis, hypertension, anaemia, abdominal pain and postpartum psychosis.
She also drew attention to perineal wound dehiscence, a condition in which an episiotomy wound reopens after childbirth instead of healing properly.
The condition may present with symptoms such as persistent pain, pus, foul smelling discharge, unexpected bleeding or difficulty controlling gas or stool when deeper muscles are affected.
“If a woman is bleeding, she can give up. We see them coming back emaciated and unkempt because there is no follow up. Sometimes their bodies smell and infection sets in,” Mrs Augustine said.
She urged mothers to attend postnatal clinics even when they feel healthy.
READ ALSO: PT Health Watch: Beyond refreshment, understanding the risks of zobo during pregnancy
Why postnatal follow up matters
Mrs Augustine said the postpartum period requires continuous medical attention because serious complications can develop after a mother has been discharged from the hospital.
According to her, postnatal follow up helps health workers detect and manage excessive bleeding, infections, poor nutrition, high blood pressure and postpartum depression before they become life threatening.
She added that strengthening postpartum care and ensuring mothers receive adequate education before discharge would improve maternal and newborn health outcomes.
“Postpartum care should be treated with the same urgency as labour and delivery,” she said.
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.
Health
Inside fragile chain holding Kano, Gombe’s immunisation systems
Published
1 day agoon
August 8, 2026By
Preport
Under the harsh April sun, the heat was oppressive in Fagge Local Government Area of Kano State. But 56-year-old Uma Usman kept walking from one compound to another, calling out familiar names, knocking gently on half-open doors and asking after children she had come to know over the years.
She is not an employee of the local Galadima Primary Health Centre. Her name does not appear on any government payroll. Yet, she has become one of the most important links in the community’s immunisation system.
Her job is to find children who missed their routine immunisation appointments.
“I know the community very well, so I follow them house by house,” Mrs Usman told PREMIUM TIMES. “If the parents don’t come, we check the register and trace the households.”
For Mrs Usman, behind every missed appointment, there is a story.
Sometimes a child is ill. Sometimes a mother cannot raise money for transport. Sometimes parents are occupied with work or family responsibilities.
“When you reach a house, you find it is not that they don’t want to come,” she said. “Something just stood in the way.”
Mrs Usman’s daily routine illustrates a broader reality observed in a PREMIUM TIMES investigation in Kano and Gombe states.

Contrary to the widespread assumption that vaccine shortages are the biggest obstacle to routine immunisation, frontline workers in the two states described a different problem. Vaccines are usually available. The challenge is ensuring children complete the immunisation schedule.
However, for many families who spoke with PREMIUM TIMES, the barrier is not acceptance but access. Long distances to health facilities, transport costs, delayed outreach activities and the daily struggle to earn a living often interrupt follow-up visits. As a result, many children receive their first vaccine but never complete the doses needed for full protection.
The consequences extend far beyond individual families.
This investigation examined routine immunisation efforts and challenges in Kano and Gombe between 2023 and 2026, drawing on field visits, interviews, official records and data from health authorities and development partners.
The period captures the continuing struggle to reach children who have never received a vaccine, as well as those who start their vaccination schedule but fail to complete it.
According to UNICEF, Nigeria has one of the world’s largest populations of zero-dose children, those who never received a routine vaccine. Its latest data shows that only about 67 per cent of surviving infants receive the third dose of the diphtheria, tetanus and pertussis (DTP3) vaccine, while coverage for the second dose of the measles vaccine is about 35 per cent.
Although routine immunisation coverage has improved in recent years, many children still receive no vaccines at all or fail to complete the schedule.
Behind those national figures are thousands of individual stories like the ones Mrs Usman encounters every week.
But the investigation found another, less visible reality.
Across communities in Kano and Gombe, routine immunisation continues largely because health workers, volunteers and community mobilisers bridge gaps created by delayed funding, difficult terrain and overstretched primary healthcare systems.
Many spend their own money to reach remote settlements. Volunteers without formal employment trace children from house to house. Outreach activities continue even when operational funds arrive months late.
Different communities, same struggle
The pattern seen in Fagge extends far beyond one community.
In Takai LGA of Kano State, reaching children who miss vaccination appointments often means travelling long distances across scattered settlements. Health workers say routine clinic sessions alone are not enough; repeated outreach visits are essential to find children who fail to return.
“There is never a time when people come and we do not have vaccines,” said Muhammad Ali, the officer-in-charge at Gamawa Health Post in neighbouring Gombe State.

Field records reviewed by PREMIUM TIMES and interviews with frontline workers showed that children scheduled for follow-up are not always reached as planned.
Health workers explained that outreach teams frequently face transport constraints, limited time, and difficult terrain, making it impossible to visit every household listed for follow-up during a single outreach exercise.
“We don’t refuse to go,” one health worker said. “But sometimes the list is longer than what we can physically cover in one outreach.”
Many children miss vaccine doses because follow-up visits could not be completed.
In Billiri LGA of Gombe State, the pattern is the same.
Health workers and volunteer mobilisers spend almost as much time searching for children who missed appointments as they do on administering vaccines.
Across these locations, one pattern persists: children often begin immunisation but fail to complete the schedule because of family challenges.

A system sustained by people
For Ignatius Essien, general manager of eHealth Systems Africa, the difficulty families face getting to health facilities helps explain the introduction of the Zero Dose Support Programme.
Mr Essien said the programme gives transport support to caregivers who bring their children for immunisation. It applies to children coming for either their first dose or subsequent doses.
“The funds are not tied to routine immunisation outcomes,” he stated.
He explained that the idea grew from what health workers repeatedly saw in the field: families who wanted to vaccinate their children but lived too far from health facilities or could not afford the fare to get there.
“Some say they cannot even afford transport fare to the clinic,” he said. “That is what stimulated the stipend.”
The support started at N500 but has since increased from N1000 to N2500 depending on the vaccine type as transport fares and the cost of living rose.
At Sansani PHC in Billiri LGA, routine immunisation sessions typically attract between 30 and 45 caregivers.

Behind those clinic days, however, lies another routine that is rarely captured in official reports —tracing children who do not return.
The facility’s Head of Immunisation, Elias Ezekiel, said health workers use immunisation registers to identify children who miss appointments from the catchment seven communities.
“From the register, if anyone misses, we follow up,” Mr Ezekiel told PREMIUM TIMES.
That work depends on outreach funding.
The health centre receives about N35,000 monthly for outreach activities, but the money is released quarterly by the State Primary Health Care Development Agency.
When PREMIUM TIMES visited, more than three months had passed without any release.
Mr Ezekiel said the delays are routinely reported through local government health authorities.
“If we stop outreach, the children will miss their vaccines,” he said.
So, staff members buy fuel and pay transport costs from their own pockets while waiting for the fund.

His account echoed those of several frontline workers interviewed across Kano and Gombe.
Vaccines are generally available, they said, but getting them to children in remote communities often depends on health workers absorbing the cost whenever operational funding is delayed.
That challenge is more difficult for facilities serving scattered settlements.
A quiet crisis in the North
The challenges confronting health workers in Kano and Gombe reflect a much wider crisis across northern Nigeria, where hundreds of thousands of children remain unreached by routine immunisation.
In April 2025, UNICEF estimated that about 53,000 children in Gombe State had never received a routine vaccine. More than half of them were in five high-risk LGAs, including Akko, where health authorities were contending with poor access to healthcare, low awareness and vaccine hesitancy.

To address the problem, the Gombe State Primary Health Care Development Agency, with support from UNICEF, launched the Fathers’ Response Team in 2024 to encourage greater male involvement in decisions about child health and immunisation.
Even so, many children continue to miss life-saving vaccines.
The challenge is even greater in Kano.
UNICEF estimates that more than 300,000 children are zero-dose, accounting for half of the burden across Kano, Katsina and Jigawa states.
UNICEF’s Chief Field Officer in Kano, Rahama Farah, said more than 600,000 children across the three states have yet to receive their first routine vaccine dose.
Many of these children live in remote or underserved communities where access to healthcare remains inconsistent.
“This is a basic fundamental child right,” Ms Farah noted.
She also warned that missed vaccinations increase vulnerability to outbreaks of preventable diseases and urged caregivers to complete immunisation schedules.
Why Kano and Gombe tell different stories
Although Kano and Gombe face similar immunisation challenges, the underlying pressures are different.
In Kano, the greatest obstacle is scale. With a population of more than 17 million people and over 600,000 births every year, health facilities operate under constant pressure.
The 2021 Multiple Indicator Cluster Survey (MICS) found that about 30.2 per cent of children in Kano are zero-dose, while only about 48 per cent complete the full routine immunisation schedule by their first birthday. National estimates indicate dropout rates of up to 31 per cent between the first and third doses of routine vaccines.

In Gombe, where the population is less than a third of Kano’s, geography plays a larger role. Communities are more dispersed, distances are longer, and access to health facilities often requires significant time and effort.
Estimates place Gombe’s zero-dose prevalence between 18 and 22 per cent, with only about 36 per cent completing full immunisation in some datasets.
Where the system weakens

The investigation found that the biggest weakness in routine immunisation is not getting children into the system.
It is keeping them in it.
Across health facilities in Kano and Gombe visited by PREMIUM TIMES, workers consistently described a system that performs relatively well at administering first doses but struggles to retain children through the full vaccination schedule.
Nationally, dropout rates between early and later vaccine doses range from about 12 to 30 per cent, depending on location.
At the Galadima PHC in Kano, Hauwa Isa, the assistant head of the facility, pointed to a solar-powered vaccine refrigerator stocked with vaccines.

“We have complete vaccines in the fridge,” she said. “We conduct immunisation three times a week and spend other days on outreach.”
“The real issue is not availability. It is continuity.”
That continuity depends on a governance system in which responsibility is shared but accountability is often blurred.
Primary health centres are under local governments, while state Primary Health Care Development Agencies oversee much of their staffing and operations. The federal government sets national policy and supports key immunisation programmes through partnerships with development agencies.
Health workers told PREMIUM TIMES that when outreach funding is delayed or operational gaps emerge, it is often difficult to determine where responsibility lies.

Money, priorities and the field reality
Over the past five years, both Kano and Gombe have recorded sharp increases in their budgets.
Official budget documents show Kano State’s spending plan rose from N221.24 billion in 2022 to N1.47 trillion in 2026, while Gombe’s grew from roughly N154.96 billion to N617.95 billion over the same period.
Those figures suggest governments have greater financial capacity to deliver public services, including primary healthcare.
Yet interviews with frontline workers across both states tell a more complicated story.
For them, the size of the budget does not matter when operational funds do not arrive when they are needed.
Outreach funding illustrates that gap.
It is the money that helps vaccines to reach children in remote communities. Health workers say when those funds are delayed, outreach activities depend on staff members improvising.
In Fagge and Takai LGAs of Kano State, workers told PREMIUM TIMES that each PHC is allocated about N7,000 a month for outreach transport.
Several months’ allocations are often paid together in arrears at the end of a quarter, long after many of the outreach visits.
In Gombe State, PHCs receive N35,000 a month for outreach transport, but the money is likewise paid quarterly.
The situation is even more difficult at health posts.
Unlike PHCs, they receive no dedicated transport allocation, according to workers interviewed by PREMIUM TIMES. Yet they are responsible for tracing children who miss appointments and carrying vaccination services to remote settlements.
When priorities compete
Funding pressures extend beyond the health sector.
Budget documents reviewed by PREMIUM TIMES show that both Kano and Gombe have made substantial allocations to debt servicing in recent years.
In the 2026 fiscal year, Kano budgeted about N69.84 billion for debt repayment, while Gombe allocated roughly N37.23 billion.
Those obligations are met before many operational funds are released to sectors such as PHCs, reducing the fiscal space available for routine service delivery.
Health workers say they experience those pressures in delayed outreach, postponed field visits and reduced operational flexibility.
Government spending priorities are also visible elsewhere.
In Kano, the state approved the purchase of 41 sport utility vehicles (SUVs) for members of the House of Assembly in 2024 at a cost of about N2.6 billion, alongside other vehicle purchases for the executive and security agencies.
In Gombe, similar procurements included 41 SUVs for lawmakers and commissioners in 2023, while more than N2 billion was allocated for vehicles for the judiciary in 2025.
Government officials have defended such purchases as necessary for governance and movement across challenging terrains.
For health workers travelling across the same terrains, however, the contrast is difficult to ignore. Many outreach teams continue to rely on motorcycles, commercial transport, or long walks to reach remote communities.
Where the system holds
Despite its weaknesses, northern Nigeria’s routine immunisation system continues to function because thousands of frontline health workers, volunteers and community mobilisers return to the same communities, often with limited resources, determined to find children who have missed their vaccines.
But sustaining that effort requires more than commitment, according to public health expert Abdulhameed Adediran, who warned that children who miss subsequent vaccine doses remain vulnerable to preventable diseases.
“A child is supposed to have three doses but has only the first dose. That child is not 33 per cent protected. That child is not protected because the first dose is supposed to last for a particular period before the next one is administered to have a complete effect,” he told PREMIUM TIMES via phone interview.
Mr Adediran said inadequate financing for PHC undermines the entire immunisation system. According to him, when outreach activities are poorly funded, children in distant communities are more likely to miss vaccinations, leaving dangerous gaps in disease prevention.
He traced many of the problems to systemic weaknesses, including poor funding, shortages of health workers, weak accountability, and inadequate infrastructure. In many facilities, he noted, community health extension workers shoulder responsibilities beyond their intended roles because of years of limited recruitment.
Mr Adeniran said immunisation programmes must be designed around the realities of the communities they serve rather than through one-size-fits-all approaches.
“People sit in Abuja and take decisions for people in those villages, and those decisions don’t necessarily work for them or are not necessarily applicable to them,” he explained, adding, “We need to start looking at a tailored, people-centred approach to our health institutions.”
Government responds
Responding to the findings, the Gombe State Primary Health Care Development Agency acknowledged that delays in releasing outreach funds sometimes occur, attributing them to administrative procedures, financial reconciliation processes and the timing of support from development partners.
The State Immunisation Officer, Abdulkarim Aliyu, said routine immunisation outreach is funded through a combination of government resources and donor support, with disbursements passing through several approval and accountability processes before reaching health facilities.

While acknowledging the effect of delayed releases, Mr Aliyu praised frontline workers who continue to provide outreach services despite funding constraints.
“We also recognise and appreciate the dedication of frontline health workers who often go the extra mile to ensure that vaccination services continue even when resources are delayed,” he said.
He said the agency has strengthened defaulter-tracking systems, expanded community mobilisation through Ward Development Committees, Community Health Influencers, Promoters and Services (CHIPS) agents and the Mama-to-Mama initiative, while holding regular review meetings to identify communities with high dropout rates and deploy targeted interventions.
Mr Aliyu added that the agency was pursuing workforce training, supportive supervision, and strategic staff deployment to address staffing shortages, while routine data validation and quality assessments are used to monitor immunisation records and identify children who miss scheduled vaccinations.
Looking ahead, he said the agency would focus on strengthening outreach services, improving community engagement, and expanding efforts to identify and vaccinate zero-dose and under-immunised children.
In Kano, the Director-General of the State Primary Health Care Management Board, Salisu Ibrahim, said outreach stipends are paid through a performance-tracking system supported by Acasus, a routine immunisation partner that monitors outreach sessions conducted by service providers.
Mr Ibrahim explained that payment delays sometimes occur because service-delivery records must first be verified before payments are processed.
He said the state has adopted several measures to reduce vaccine dropout rates, including ensuring that planned immunisation sessions are conducted, expanding public awareness campaigns, and addressing practices that contribute to missed vaccination opportunities.
While acknowledging financial pressures, he said the current administration of Governor Abba Yusuf increased outreach stipends from N1,000 to N4,000 per session to help health workers cope with rising transportation and operational costs.
He added that the board also conducts monthly data validation exercises, review meetings and independent surveys to identify service gaps and strengthen routine immunisation in underserved communities.
Whether those efforts will be enough to reduce the number of children missing vaccines remains uncertain.
What is clear, however, is that across communities in Kano and Gombe, routine immunisation continues to depend heavily on the persistence of health workers, volunteers and caregivers who keep showing up despite funding delays, staffing shortages and the difficulties of reaching remote settlements.
For many children, completing vaccination depends on that fragile chain.
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.
Trending
-
News3 days ago
Governor Mutfwang Begins Strategic Assessment to Restore Plateau’s Heritage, Boost Tourism
-
Health3 days ago
UNFPA partners Lagos, GoMed to expand reproductive health services for Nigerian students
-
Business2 days ago
Nigeria, Canada expand air deal, facilitate direct flights
-
News3 days ago
‘We won’t tolerate such’ – City Boy Movement sacks Oyo coordinator for insulting Tinubu, son


